Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting

Yen Holicka; Elisa Tagliani; Daniela Maria Cirillo; Vlad Nikolayevskyy

doi:10.1016/j.tube.2022.102185

Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting

Yen Holicka^*, Elisa Tagliani, Daniela Maria Cirillo, Vlad Nikolayevskyy

^*Corresponding author for this work

UK Health Security Agency

Research output: Contribution to journal › Article › peer-review

4 Downloads (Pure)

Abstract

This study aims to gather observational evidence of Whole Genome Sequencing's (WGS) impact in the pathogen identification, antimicrobial resistance profiling and transmission tracking from its users’ observation within the diagnostic setting of the European reference laboratories for tuberculosis. Sixteen laboratories that have been utilising WGS in their tuberculosis diagnostic laboratory were invited and twelve (75%) responded to our online questionnaire. Key findings include its primary utilisation for drug resistance prediction and epidemiological services; Mtb surveillance and outbreak investigation. 92% reported significant improvements to the performance of TB drug resistance testing and the reduction of false clustering. Despite the public health benefits of the WGS technology was largely positive in non-tuberculous mycobacteria disease management, multidrug-resistant TB patient management, reputational aspects and turnaround times, further studies are required to review the financial impact as various regulations and service aspects have added to the complexity to disentangle this aspect.

Original language	English
Article number	102185
Journal	Tuberculosis
Volume	134
Early online date	21 Feb 2022
DOIs	https://doi.org/10.1016/j.tube.2022.102185
Publication status	Published - May 2022

Bibliographical note

Funding Information: The authors are thankful for the support from ECDC through the ERLTB-Net-2 funding infrastructure ( ECDC/GRANT/2018/001 ). This publication reflects only the authors' views. ECDC is not responsible for any use that may be made by the information it contains.

Open Access: This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

Publisher Copyright: © 2022 The Authors. Published by Elsevier Ltd.

Citation: Holicka, Yen, et al. "Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting." Tuberculosis 134 (2022): 102185.

DOI: https://doi.org/10.1016/j.tube.2022.102185

Keywords

Laboratory diagnostic
Next generation sequencing
Tuberculosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tube.2022.102185Licence: CC BY-NC-ND

Holicka2022UtilityOfTheWholeGenomeSequencingBasedMethodologiesInRoutineTuberculosisFinal published version, 1.53 MBLicence: CC BY-NC-ND

Cite this

@article{0bcf46094e1a4d71a037f2dadb82739e,

title = "Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting",

abstract = "This study aims to gather observational evidence of Whole Genome Sequencing's (WGS) impact in the pathogen identification, antimicrobial resistance profiling and transmission tracking from its users{\textquoteright} observation within the diagnostic setting of the European reference laboratories for tuberculosis. Sixteen laboratories that have been utilising WGS in their tuberculosis diagnostic laboratory were invited and twelve (75%) responded to our online questionnaire. Key findings include its primary utilisation for drug resistance prediction and epidemiological services; Mtb surveillance and outbreak investigation. 92% reported significant improvements to the performance of TB drug resistance testing and the reduction of false clustering. Despite the public health benefits of the WGS technology was largely positive in non-tuberculous mycobacteria disease management, multidrug-resistant TB patient management, reputational aspects and turnaround times, further studies are required to review the financial impact as various regulations and service aspects have added to the complexity to disentangle this aspect.",

keywords = "Laboratory diagnostic, Next generation sequencing, Tuberculosis",

author = "Yen Holicka and Elisa Tagliani and Cirillo, {Daniela Maria} and Vlad Nikolayevskyy",

note = "Funding Information: The authors are thankful for the support from ECDC through the ERLTB-Net-2 funding infrastructure ( ECDC/GRANT/2018/001 ). This publication reflects only the authors' views. ECDC is not responsible for any use that may be made by the information it contains. Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Publisher Copyright: {\textcopyright} 2022 The Authors. Published by Elsevier Ltd. Citation: Holicka, Yen, et al. {"}Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting.{"} Tuberculosis 134 (2022): 102185. DOI: https://doi.org/10.1016/j.tube.2022.102185",

year = "2022",

month = may,

doi = "10.1016/j.tube.2022.102185",

language = "English",

volume = "134",

journal = "Tuberculosis",

issn = "1472-9792",

publisher = "Elsevier",

}

TY - JOUR

T1 - Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting

AU - Holicka, Yen

AU - Tagliani, Elisa

AU - Cirillo, Daniela Maria

AU - Nikolayevskyy, Vlad

N1 - Funding Information: The authors are thankful for the support from ECDC through the ERLTB-Net-2 funding infrastructure ( ECDC/GRANT/2018/001 ). This publication reflects only the authors' views. ECDC is not responsible for any use that may be made by the information it contains. Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Publisher Copyright: © 2022 The Authors. Published by Elsevier Ltd. Citation: Holicka, Yen, et al. "Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting." Tuberculosis 134 (2022): 102185. DOI: https://doi.org/10.1016/j.tube.2022.102185

PY - 2022/5

Y1 - 2022/5

N2 - This study aims to gather observational evidence of Whole Genome Sequencing's (WGS) impact in the pathogen identification, antimicrobial resistance profiling and transmission tracking from its users’ observation within the diagnostic setting of the European reference laboratories for tuberculosis. Sixteen laboratories that have been utilising WGS in their tuberculosis diagnostic laboratory were invited and twelve (75%) responded to our online questionnaire. Key findings include its primary utilisation for drug resistance prediction and epidemiological services; Mtb surveillance and outbreak investigation. 92% reported significant improvements to the performance of TB drug resistance testing and the reduction of false clustering. Despite the public health benefits of the WGS technology was largely positive in non-tuberculous mycobacteria disease management, multidrug-resistant TB patient management, reputational aspects and turnaround times, further studies are required to review the financial impact as various regulations and service aspects have added to the complexity to disentangle this aspect.

AB - This study aims to gather observational evidence of Whole Genome Sequencing's (WGS) impact in the pathogen identification, antimicrobial resistance profiling and transmission tracking from its users’ observation within the diagnostic setting of the European reference laboratories for tuberculosis. Sixteen laboratories that have been utilising WGS in their tuberculosis diagnostic laboratory were invited and twelve (75%) responded to our online questionnaire. Key findings include its primary utilisation for drug resistance prediction and epidemiological services; Mtb surveillance and outbreak investigation. 92% reported significant improvements to the performance of TB drug resistance testing and the reduction of false clustering. Despite the public health benefits of the WGS technology was largely positive in non-tuberculous mycobacteria disease management, multidrug-resistant TB patient management, reputational aspects and turnaround times, further studies are required to review the financial impact as various regulations and service aspects have added to the complexity to disentangle this aspect.

KW - Laboratory diagnostic

KW - Next generation sequencing

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85126784586&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2022.102185

DO - 10.1016/j.tube.2022.102185

M3 - Article

C2 - 35247779

AN - SCOPUS:85126784586

VL - 134

JO - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

M1 - 102185

ER -

Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this